| Original language | English |
|---|---|
| Pages (from-to) | 1454-1456 |
| Number of pages | 3 |
| Journal | Clinical Microbiology and Infection |
| Volume | 25 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Dec 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Microbiology and Infection, Vol. 25, No. 12, 12.2019, p. 1454-1456.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Clinical interpretation of enteric molecular diagnostic tests
AU - Tarr, G. A.M.
AU - Tarr, P. I.
AU - Freedman, S. B.
N1 - Funding Information: Outside the current work, P.I.T. reports personal fees as a consultant and membership on the scientific advisory board for MediBeacon Inc.; he also holds equity in the company. P.I.T. and S.B.F. report personal fees as consultants for Takeda Pharmaceuticals, and P.I.T. reports consulting fees for the Bill & Melinda Gates Foundation on infant infections. S.B.F. reports non-financial support from Luminex Corporation, BioMérieux and Copan Diagnostics to support research activities. In addition, PIT has a patent 20190142976 pending to MediBeacon Inc., and is an unpaid consultant to Immunova relating to development of a therapeutic agent for Shiga toxin-producing E. coli. S.B.F. is supported by the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness. Funding Information: Outside the current work, P.I.T. reports personal fees as a consultant and membership on the scientific advisory board for MediBeacon Inc. ; he also holds equity in the company. P.I.T. and S.B.F. report personal fees as consultants for Takeda Pharmaceuticals , and P.I.T. reports consulting fees for the Bill & Melinda Gates Foundation on infant infections. S.B.F. reports non-financial support from Luminex Corporation, BioMérieux and Copan Diagnostics to support research activities. In addition, PIT has a patent 20190142976 pending to MediBeacon Inc., and is an unpaid consultant to Immunova relating to development of a therapeutic agent for Shiga toxin-producing E. coli. S.B.F. is supported by the Alberta Children’s Hospital Foundation Professorship in Child Health and Wellness.
PY - 2019/12
Y1 - 2019/12
UR - http://www.scopus.com/inward/record.url?scp=85072595435&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2019.08.018
DO - 10.1016/j.cmi.2019.08.018
M3 - Comment/debate
C2 - 31491461
AN - SCOPUS:85072595435
SN - 1198-743X
VL - 25
SP - 1454
EP - 1456
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 12
ER -